Home Contact Us 中文 English
Yourlocation:Home >News> Trimebutine maleate experiment constipation

Trimebutine maleate experiment constipation

Time:2015/9/30 7:23:23

in constipated patients, Trimebutine maleate (600mg/day) significantly improved abdominal symptoms after an 8-week course of treatment; the improvement of symptoms was

correlated with its action on colonic transit time measured by the pellet msthod." in another study including constipated patients, Trimebutine maleate accelerated the colonic

transit time but failed to increase the frequency of bowel movements. 77 finally, in a trial in ibs patients, the stool frequency was increased after Trimebutine maleate."'"

in a recent study, 24 patients (12 with normal colonic transit and 12 with delayed transit) with chronic idiopathic constipation were evaluated by measuring their stool frequency, colonic transit time and myoelectrical activity.'?' they were treated for 2 months with placebo and Trimebutine maleate (100 mg, twice daily) in a crossover design. Trimebutine maleate significantly shortened the colonic transit time and stimulated propagated myoelectrical activity, but only in patients with delayed transit times. in view of these results, Trimebutine maleate may be helpful for patients with chronic idiopathic constipation and delayed colonic transit time.

in an open, non-placebo-controlled study, Trimebutine maleate effectively relieved constipation in ibs patients with moderate constipation (three bowel movements/week). after one month of therapy (Trimebutine maleate, 300 mg/day,orally), stool frequency increased in 86% of patients. clinical interview revealed that this objective improvement of the number of stools was considered by the patients to constitute an improvement of their constipationrelated symptoms in 82.5% of cases.':" global assessment of the efficacy of Trimebutine maleate in the treatment ofibs-related symptoms (abdominal pain, bloating, altered bowel habit) was considered to be good in 78.5% of patients and moderate in another 18.1%. improvement was obtained in most patients after 2 days of treatment.